Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Here are some of the major companies whose stocks moved on the week’s news.
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback